[ 1 ] Shimanovsky A, Dasanu CA. Updates on immunotherapy in non-small cell lung cancer[J]. Expert Opin Biol Ther, 2014, 14(4): 411-418.
[2]
[ 2 ] Villaruz LC, Kalyan A, Zarour H, et al. Immunotherapy in lung cancer[J]. Translat Lung Cancer Res, 2014, 3(1): 2-14.
[3]
[ 4 ] Borghaei H, Lynch TJ, Naiyer AR, et al. A phase Ⅲ comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC)[C]. ASCO Annual Meeting Abstract, 2013, UN: TPS8122.
[4]
[ 5 ] Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366(26): 2455-2465.
[5]
[ 6 ] Spigel DR, Gettinger SN, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)[C]. ASCO Annual Meeting Abstract, 2013, UN: no8008.
[6]
[ 7 ] Rodriguez PC, Neninger E, García B, et al. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an epidermal growth factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients[J]. J Immune Based Ther Vaccines, 2011, 9: 7.
[7]
[ 8 ] Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, et al. PhaseⅡ randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2008, 26(9): 1452-1458.
[8]
[ 9 ] Ramos TC, Neninger E, Acosta S, et al. EGF-based cancer vaccine for advanced NSCLC: results from a phaseⅢ trial[C]. ASCO Annual Meeting Abstract, 2012, UN: no2527.
[9]
Wu YL, Park K, Soo RA, et al. INSPIRE: a phaseⅢ study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stageⅢ non-small cell lung cancer[J]. BMC Cancer, 2011, 11(1): 430.
[10]
PhaseⅢ LucanixTM vaccine therapy in advanced non-small-cell lung cancer (NSCLC) Following Front-line Chemotherapy (STOP)[DB/OL]. http://clinicaltrials.gov/show/NCT00676507.
[11]
Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape[J]. Sci Transl Med, 2012, 4(127): 127ra37.
[12]
Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phaseⅡ study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stageⅠB/Ⅱ non-small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2007, 25(18S): 7554.
[13]
Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase Ⅱstudy of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer[J]. J Clin Oncol, 2006, 24(29): 4721-4730.
[14]
[ 3 ] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of Anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454.
[15]
Vansteenkiste J, Zielinski M, Linder A, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phaseⅡ randomized study results[J]. J Clin Oncol, 2013, 31(19): 2396-2403.
[16]
Tyagi P, Mirakhur B. MAGRIT: the largest-ever phaseⅢ lung cancer trial aims to establish a novel tumor-specific approach to therapy[J]. Clin Lung Cancer, 2009, 10(5): 371-374.
[17]
Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells[J]. Oncogene, 2010, 29(20): 2893-2904.
[18]
Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy[J]. Expert Rev Vaccines, 2005, 4(4): 493-502.
[19]
Butts C, Murray N, Maksymiuk A, et al. Randomized phaseⅡB trial of BLP25 liposome vaccine in stage ⅢB and Ⅳ non-small-cell lung cancer[J]. J Clin Oncol, 2005, 23(27): 6674-6681.
[20]
Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage ⅢB or Ⅳ non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phaseⅡB randomized, multicenter, open-label trial[J]. J Cancer Res Clin Oncol, 2011, 137(9): 1337-1342.
[21]
Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage Ⅲ non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2014, 15(1): 59-68.
[22]
Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial[J]. Lancet Oncol, 2011, 12(12): 1125-1133.
[23]
Elisabeth AQ, Nemunaitis JJ, Burzykowski T, et al. TIME: a phaseⅡb/Ⅲ randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stageⅣ non-small cell lung cancer (NSCLC)[C]. ASCO Annual Meeting Abstract, 2012. UN: TPS7610.
[24]
Phase Ⅱb/Ⅲ of tg4010 immunotherapy in patients with stage Ⅳ non-small cell lung cancer (time)[DB/OL]. http://www.clinicaltrials.gov/ct2/show/NCT01383148term=TG4010+TIME&rank=1.
[25]
Nemunaitis J, Nemunaitis M, Senzer N, et al. PhaseⅡ trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients[J]. Cancer Gene Ther, 2009, 16(8): 620-624.
[26]
Kong F, Jirtle RL, Huang DH, et al. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma[J]. Cancer, 1999, 86(9): 1712-1719.
[27]
O’ brien MR, Saini A, Smith IE, et al. A randomized phase Ⅱ study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma[J]. Br J Cancer, 2000, 83(7): 853.
[28]
Hirsh V, Paz-Ares L, Boyer M, et al. Randomized phaseⅢ trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer[J]. J Clin Oncol, 2011, 29(19): 2667-2674.
[29]
Hirsh V, Boyer M, Rosell R, et al. Randomized phaseⅢ trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first line treatment of advanced non-small cell lung cancer (NSCLC)[C]. J Clin Oncol (Meeting Abstracts), 2008(Suppl 15): 8016.
